Cardiovascular diseases (CVD) are the number one cause of morbidity and death
worldwide. As estimated by the WHO, the global death rate from CVD is 31% wherein, a …

Cardiovascular disease, particularly coronary artery dis-ease resulting from accelerated
atherosclerosis, is the leading cause of morbidity and mortality in patients with diabetes …

Primarily used in the treatment of intermittent claudication, cilostazol is a 2-oxyquinolone
derivative that works through the inhibition of phosphodiesterase III and related increases in …

Daily administration of low-dose aspirin has proved to be beneficial in preventing recurrent
cardiovascular events. However, the role of aspirin for primary prevention in patients with no …

In the normal course of the delivery of care, anesthesiologists encounter many patients who
are receiving drugs that affect platelet function as a fundamental part of primary and …

Background: Aspirin and antagonists of platelet ADP P2Y 12 receptors are often
coprescribed for protection against thrombotic events. However, blockade of platelet P2Y 12 …

Platelet activation plays a key role in atherothrombosis in type 2 diabetes mellitus (T2DM)
and increased in vivo platelet activation with enhanced thromboxane (TX) biosynthesis has …

Our knowledge of the mechanisms of platelet-mediated thrombosis has increased
dramatically over the last 40 years. This increased understanding has identified treatment …

Introduction After cardiac arrest due to acute coronary syndromes (ACS) therapeutic
hypothermia (HT) is the standard care to reduce neurologic damage. Additionally, the …

Coronary artery disease (CAD) is one of the leading causes of death globally, and
antiplatelet therapy is crucial for both its prevention and treatment. Antiplatelet drugs such as …